GlassScriptPhysician profile
Samer B Blackmon
NPI 1104935063
$4,814.10
in general payments reported to CMS, 2019-2025
35 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $603 · 2021: $442 · 2022: $640 · 2023: $976 · 2024: $1,276 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.52 |
| Education | $150.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $470.22 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $397.51 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $394.40 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $376.97 | 2022-2024 | |
| Astellas Pharma US INC | $361.22 | 2019-2024 | Veozah |
| Abbvie INC. | $333.00 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $327.31 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.36 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $278.64 | 2019-2024 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $236.28 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Allergan, INC. | $192.46 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $129.48 | 2023-2024 | Quviviq |
| Amgen INC. | $122.82 | 2019-2024 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $103.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $102.84 | 2022-2023 | Spravato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $81.33 | 2020-2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $75.00 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $62.70 | 2019-2020 | |
| Procept Biorobotics Corporation | $57.38 | 2023 | Aquabeam Robotic System |
| Abbott Laboratories | $57.12 | 2022-2024 | Proclaim |
| Merck Sharp & Dohme LLC | $49.04 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.55 | 2021 | |
| Exact Sciences Corporation | $42.65 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $33.92 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $32.67 | 2022-2024 | Livalo |
| Axonics, INC. | $27.35 | 2022 | |
| Corium, LLC | $23.50 | 2025 | Azstarys |
| Hologic Sales and Service, LLC | $19.74 | 2019 | |
| Amneal Pharmaceuticals LLC | $19.58 | 2022 | |
| Kaleo, INC. | $15.34 | 2020 | |
| Impel Pharmaceuticals INC. | $14.55 | 2023 | Trudhesa |
| Currax Pharmaceuticals LLC | $14.23 | 2021 | |
| Dexcom, INC. | $13.76 | 2023 | Dexcom G6 Transmitter |
| Shire North American Group INC | $13.45 | 2019 | |
| Phadia US INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Blackmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.